According to new research from Raymond James, one digital health company may be entering a window of opportunity that investors should not overlook. The analysts believe Doximity, the professional networking and workflow platform used by U.S. physicians, has been oversold and now offers a compelling valuation setup for long-term investors.

The firm upgraded the stock to a strong buy and argued that the recent pullback does not reflect the underlying resilience of the business or its future revenue opportunities. For readers looking for exposure to digital healthcare, software, and AI driven medical workflows, this analysis helps explain why Doximity could be positioned for meaningful upside.

Significant Dislocation

Raymond James lifted Doximity to a strong buy from outperform, even after trimming its price target from 75 dollars to 65 dollars. That still leaves roughly 40 percent potential upside from Thursday’s close. Analyst Brian Peterson said his call was driven by what he described as a “significant dislocation” following the company’s fiscal second quarter results in May.

Peterson highlighted that at current levels, the stock trades at roughly 25 times free cash flow, which he views as unusually attractive for a profitable, high margin vertical software company that dominates its niche. In his words, the shares are “too compelling to ignore.”

He added that Doximity stands out because “Doximity has all 3 Ms of a core long-term holding (Moat, Margin, and Management Team), and we think the recent pullback that has shares at a discount to the vertical software group is too great to ignore.” Raymond James also noted it is unusual for Doximity to trade at such a steep discount given the company historically commanded a premium relative to similar software names.

Seasonal Revenue Patterns

Some investors have raised questions about the company’s seasonal revenue patterns and whether strong seasonality could challenge future predictability. Peterson pushed back on this concern, writing that “seasonal shifts are not indicative of longer-term growth rates.” He said the firm believes Doximity’s long-term growth outlook remains intact and may even be improving.

He pointed to several factors that strengthen visibility for multi-year expansion. “While the company has consistently grown at 2-3x digital budgets, ramping workflow adoption, multi-product expansion and client portal benefits all suggest that these share gains are durable in nature,” Peterson said.

For investors, understanding these growth engines matters. Doximity has spent years expanding beyond physician networking into tools that support referrals, scheduling, telehealth, and clinical workflows. That shift turns the platform from a media-driven business into a recurring software and workflow provider. This is precisely the kind of transformation Wall Street rewards with higher multiples when execution remains strong.

Why AI Matters

Raymond James also emphasized one theme your audience cares about: monetizing artificial intelligence. The analyst believes AI driven tools could become a multi-year catalyst that supports higher revenue per customer and improved profitability.

Doximity has already begun integrating generative AI into its physician tools. These include message drafting, chart summarization, scheduling features, and referral workflows. As more health systems and medical groups adopt these capabilities, the firm expects the platform’s value to increase and stickiness to strengthen.

AI monetization is still in its early innings across most digital health companies, but Doximity’s large and highly engaged user base gives it a measurable advantage.

Bottom Line

Doximity is a profitable, cash generating, category leading software platform with a long runway in digital health. The stock selloff created a valuation gap that Raymond James believes is attractive for long-term investors who want exposure to healthcare technology, physician workflows, and emerging AI monetization.

The firm’s strong buy rating signals that Wall Street sees meaningful upside potential at these levels. For investors looking for stability paired with growth, Doximity may deserve a spot on the watchlist for the months ahead.